Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (13561)	10/27/2004 6:00:19 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

I've stayed out of it. Me too. But I suppose there's some small chance that they might reach overall significance if their subgroup continues to do really well. If that happens the stock would take off. One concern I've always had is how the FDA would react to their "individualized" therapy from a manufacturing point of view. Companies have a hard enough time on manufacturing when they are trying to make a standardized product. So if they are successful in their new trial (and of course as an aging male I hope they are) there might still be a short play (from much higher levels of course) further down the road. Peter